Virtual conferences democratize access to science. World View from Deborah L. Johnson, President and CEO of KeystoneSymp
In March 2020, the onset of the COVID-19 pandemic forced the abrupt cancellation of in-person conferences. The Keystone Symposia, like other conference organizations, grappled with how to keep the scientific community engaged with each other in the absence of face-to-face gatherings. At the time, the exchange of scientific research was perhaps more important than ever, as scientists and clinicians raced to understand COVID-19 and develop novel drugs and vaccines against SARS-CoV-2.
eSymposia recapitulated the essence of almost 50 years of in-person events. Our experience with virtual events over the previous five years, in the form of SciTalks and ePanels, had positioned us well for converting our conferences to fully virtual events. But a major challenge was the substantial increase in production preparation time.
83% of attendees reported that they learned something at their meeting that would accelerate their research or change the direction of one of their projects, consistent with the results for in-person events. This is a core measure of the success of a scientific meeting, whether in person or virtual, and signifies scientific progress that would have been lost in the absence of conferences during the pandemic.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Brain lesions disrupting addiction map to a common human brain circuit - Nature MedicineLesions resulting in addiction remission occur in multiple different brain locations but map to a specific brain circuit. JJoutsa and foxmdphd from UniTurku and harvardmed
Lire la suite »
How better pandemic and epidemic intelligence will prepare the world for future threats - Nature MedicineA new approach to pandemic and epidemic intelligence is needed that includes modern approaches to surveillance and risk assessment, as well as improved trust and cooperation between stakeholders and society.
Lire la suite »
Questions of accountability and transparency in the US organ donation and transplantation system - Nature MedicineQuestions of accountability and transparency in the US organ donation and transplantation system. Correspondence from DrMaceyLevan and colleagues nyugrossman nyulangone
Lire la suite »
Diversity, equity and inclusion actions from the NCATS Clinical and Translational Science awarded programs - Nature MedicineDiversity, equity and inclusion actions from the NCATS Clinical and Translational Science awarded programs. Correspondence from L. Ebony Boulware and colleagues DukeMedSchool
Lire la suite »
A randomized controlled trial to test financial incentives for COVID-19 vaccination in Ghana - Nature MedicineA randomized controlled trial to test financial incentives for COVID-19 vaccination in Ghana. Correspondence from pmc868 and colleagues Oxford_NDPH UnivofGh
Lire la suite »
Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial - Nature MedicineFor infants with three copies of SMN1 at risk for spinal muscular atrophy (SMA) type 1, onasemnogene abeparvovec improves ventilator-free survival and nutritional/respiratory independence and allows motor development indistinguishable from healthy children without SMA.
Lire la suite »